MASI: Danaher’s $180-a-share bet on smart patient monitoring

The thesis

Masimo (MASI) just went from stand‑alone stock to part of industrial giant Danaher in a cash deal that values it around $9.9 billion at $180 per share.[4][5][7] Danaher isn’t paying that kind of money for nothing: Masimo’s core business is clever hospital gear like pulse oximeters and patient‑monitoring systems that have been growing steadily, with Q1 2026 revenue of about $403.6 million and earnings per share of $1.08.[2] Over the past year the stock climbed roughly 16% as the deal story developed and legal challenges around the merger were worked through.[4][6] The bull case now is simple: Danaher sees Masimo’s tech as a key growth engine, especially as hospitals want more data‑driven monitoring and remote care.[2][4]

Everyone wishes they'd bought Nvidia early. Here's how to spot the next one.

The biggest winners of the last decade had one thing in common. Our data follows those exact moves — and turns them into 10 names to watch right now.

The big names in the AI, Space, Nuclear and Robotics race. The window to get in early is closing fast. Don't wait.

See the top 10 stocks now — free ›

💡 Why this matters

If you’ve ever had your finger clipped into a little device to check your oxygen levels, you’ve probably met Masimo’s world. They build the sensors and monitors that quietly watch over patients in hospitals and, increasingly, at home.[4] As healthcare gets more digital and data‑heavy, and as aging populations need more constant monitoring, companies that can reliably track your vital signs are in a sweet spot.[2][4] A big, respected buyer like Danaher stepping up with real cash is a vote of confidence in that long‑term trend—and in Masimo’s role in it.[4][7]

▲ Catalysts

+ Danaher’s all‑cash acquisition at $180 per MASI share closed June 10, 2026, turning Masimo into a Danaher subsidiary.[4][5]
+ Q1 2026 results: about $403.6M revenue and $1.08 earnings per share, showing improving profitability.[2]
+ Analysts kept a Buy consensus with a $188 price target around July 10, 2026, reflecting confidence in Masimo’s value.[7]
+ Masimo’s revenue over the last year climbed to roughly $1.56B with net margin improving to about 13.9%.[2]

▼ Risks

! MASI is being cashed out at $180; upside beyond the deal price is limited unless terms change.[4][5][7]
! Integration risk: Masimo now depends on Danaher’s decisions, priorities, and cost‑cutting once fully absorbed.[4][6]
! Any hospital spending slowdown or healthcare budget pressure could weigh on Masimo’s growth under Danaher.[2][8]

🎯 One thing to take away

Here’s the simple version: Masimo makes the hospital gadgets that quietly keep track of your breathing, oxygen levels, and other vital signs. The business has been improving, with early‑2026 sales over $400 million in a single quarter and better profits than last year.[2] A big industrial player, Danaher, liked that story enough to buy the whole company for $180 per share in cash, valuing it at nearly $10 billion.[4][5][7] For existing MASI shareholders, this is mostly about locking in that deal price and understanding what, if anything, could change it. For folks watching the space, it’s a sign that “smart” patient monitoring and health data tools are valuable territory—but MASI itself is now basically a done takeover, not a long‑term independent growth stock anymore.[4][6]

Data sources & methodology

All figures derive from official, public-domain government filings. Read our methodology for how we collect, process and score this data. See the methodology →

TZ Researched & published by TradesZ Research

Want our premium picks too?

Pro subscribers get our strongest pre-pop ideas + real-time buy-zone alerts.

Thinking about MASI?

Our data likes 10 other stocks even more right now — under-the-radar names we believe have monster upside potential. Get the free list before the crowd catches on.

Show me the 10 stocks — free →

Free · no credit card · unsubscribe in one click

Not investment advice. We share research and analyses for educational purposes. Investing in stocks involves risk, including possible loss of capital. Always do your own research.